Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer

被引:18
|
作者
Tahkola, Kyosti [1 ,2 ]
Ahtiainen, Maarit [3 ]
Kellokumpu, Ilmo [1 ]
Mecklin, Jukka-Pekka [1 ,4 ]
Laukkarinen, Johanna [2 ,5 ]
Laakkonen, Joni [6 ,7 ]
Kenessey, Istvan [6 ,7 ]
Jalkanen, Sirpa [6 ,7 ]
Salmi, Marko [6 ,7 ]
Bohm, Jan [8 ]
机构
[1] Cent Finland Cent Hosp, Dept Surg, Keskussairaalantie 19, Jyvaskyla 40620, Finland
[2] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland
[3] Cent Finland Cent Hosp, Dept Educ & Res, Jyvaskyla, Finland
[4] Univ Jyvaskyla, Sport & Hlth Sci, Jyvaskyla, Finland
[5] Tampere Univ Hosp, Dept Gastroenterol & Alimentary Tract Surg, Tampere, Finland
[6] Univ Turku, MediCity Res Lab, Turku, Finland
[7] Univ Turku, Inst Biomed, Turku, Finland
[8] Cent Finland Cent Hosp, Dept Pathol, Jyvaskyla, Finland
关键词
Pancreatic cancer; Microenvironment; CD73; PD-L1; Prognosis; ADENOSINE; CELLS; GENERATION; HALLMARKS; SURVIVAL; INVASION; CD39;
D O I
10.1007/s00428-020-02888-4
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Immune suppressing molecule CD73 is overexpressed in various cancers and associated with poor survival. Little is so far known about the predictive value of CD73 in pancreatic ductal adenocarcinoma (PDAC). The purpose of this study was to investigate the prognostic significance of CD73 in PDAC. The study material consisted of 110 radically treated patients for PDAC. Tissue microarray blocks were constructed and stained immunohistochemically using CD73 antibody. Staining intensity and numbers of stained tumour cells, inflammatory cells, stroma, and blood vessels were assessed. High-level CD73 expression in tumour cells was positively associated with PD-L1 expression, perineural invasion, and histopathological grade. CD73 positivity in tumour-infiltrating lymphocytes was significantly associated with lymph node metastasis. Lymphocytic CD73 positivity was also associated with staining positivity in both stroma and vascular structures. In addition, CD73 positivity in vascular structures and stroma were associated with each other. There were no significant associations between CD73 positive tumour cells and CD73 positivity in any other cell types. PD-L1 expression was associated with CD73 staining positivity in stroma (p = 0.007) and also with histopathological grade (p = 0.033) and T class (p = 0.016) of the primary tumour. CD73 positivity in tumour cells was significantly associated with poor disease-specific (p = 0.021) and overall survival (p = 0.016). In multivariate analysis, CD73 positivity in tumour cells was an independent negative prognostic factor together with histopathological grade, TNM stage, and low immune cell score. In conclusion, high CD73 expression in tumour cells is associated with poor survival in PDAC independently of the number of tumour-infiltrating lymphocytes or TNM stage.
引用
收藏
页码:209 / 217
页数:9
相关论文
共 50 条
  • [31] Prognostic value of PD-L1 expression in patients with anal cancer: a meta-analysis
    Gong, Siqi
    Song, Jiafeng
    BIOMARKERS IN MEDICINE, 2024, 18 (07) : 333 - 344
  • [32] PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer
    Woodford, Rachel
    Zhou, Deborah
    Lord, Sarah J.
    Marschner, Ian
    Cooper, Wendy A.
    Lewis, Craig R.
    John, Thomas
    Yang, James Chih-Hsin
    Lee, Chee Khoon
    FUTURE ONCOLOGY, 2022, 18 (14) : 1793 - 1799
  • [33] Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma
    Han, Seunggu J.
    Reis, Gerald
    Kohanbash, Gary
    Shrivastav, Shruti
    Magill, Stephen T.
    Molinaro, Annette M.
    McDermott, Michael W.
    Theodosopoulos, Philip V.
    Aghi, Manish K.
    Berger, Mitchel S.
    Butowski, Nicholas A.
    Barani, Igor
    Phillips, Joanna J.
    Perry, Arie
    Okada, Hideho
    JOURNAL OF NEURO-ONCOLOGY, 2016, 130 (03) : 543 - 552
  • [34] The expression of PD-L1 in patients with castrate prostate cancer treated with enzalutamide
    Richter, Igor
    Jirasek, Tomas
    Havlickova, Ivana
    Curcikova, Radmila
    Samal, Vladimir
    Dvorak, Josef
    Bartos, Jiri
    JOURNAL OF BUON, 2018, 23 (06): : 1796 - 1802
  • [35] The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis
    He-Li Gao
    Liang Liu
    Zi-Hao Qi
    Hua-Xiang Xu
    Wen-Quan Wang
    Chun-Tao Wu
    Shi-Rong Zhang
    Jin-Zhi Xu
    Quan-Xing Ni
    Xian-Jun Yu
    Hepatobiliary & Pancreatic Diseases International, 2018, 17 (02) : 95 - 100
  • [36] The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer
    Kazuyuki Matsumoto
    Toshiaki Ohara
    Masayoshi Fujisawa
    Akinobu Takaki
    Masahiro Takahara
    Noriyuki Tanaka
    Hironari Kato
    Shigeru Horiguchi
    Ryuichi Yoshida
    Yuzo Umeda
    Soichiro Fushimi
    Takahito Yagi
    Akihiro Matsukawa
    Hiroyuki Okada
    Journal of Gastroenterology, 2019, 54 : 1019 - 1028
  • [37] Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer
    Kesar, Nikolina
    Winkelmann, Ria
    Oppermann, Julius
    Ghanaati, Shahram
    Martin, Daniel
    Neumayer, Thomas
    Balster, Sven
    Roedel, Claus
    Roedel, Franz
    von der Gruen, Jens
    Balermpas, Panagiotis
    ORAL ONCOLOGY, 2020, 111
  • [38] The Predictive Value of CD3+/CD8+Lymphocyte Infiltration and PD-L1 Expression in Colorectal Cancer
    Liu, Jihong
    Li, Jinbang
    Luo, Feng
    Wu, Shigang
    Li, Bingquan
    Liu, Kunping
    CURRENT ONCOLOGY, 2023, 30 (11) : 9647 - 9659
  • [39] Prognostic Value of PD-L1 in Patients with Hepatocellular Carcinoma
    Pei, Renguang
    Zhang, Weixuan
    Wang, Sufen
    Huang, Xi
    Zou, Yinghua
    CLINICAL LABORATORY, 2019, 65 (05) : 693 - 698
  • [40] PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients
    Sznurkowski, Jacek J.
    Zawrocki, Anton
    Sznurkowska, Katarzyna
    Peksa, Rafal
    Biernat, Wojciech
    ONCOTARGET, 2017, 8 (52): : 89903 - 89912